Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

C4 Therapeutics Inc (CCCC)

C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 278,827
  • Shares Outstanding, K 70,589
  • Annual Sales, $ 20,760 K
  • Annual Income, $ -132,490 K
  • EBIT $ -119 M
  • EBITDA $ -121 M
  • 60-Month Beta 2.92
  • Price/Sales 13.08
  • Price/Cash Flow N/A
  • Price/Book 1.12

Options Overview Details

View History
  • Implied Volatility 111.57% ( -46.09%)
  • Historical Volatility 89.00%
  • IV Percentile 38%
  • IV Rank 26.30%
  • IV High 401.71% on 02/05/24
  • IV Low 8.04% on 07/12/24
  • Put/Call Vol Ratio 15.85
  • Today's Volume 219
  • Volume Avg (30-Day) 256
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 14,180
  • Open Int (30-Day) 12,317

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.44
  • Number of Estimates 5
  • High Estimate -0.26
  • Low Estimate -0.59
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +35.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.61 +9.42%
on 12/18/24
5.10 -22.55%
on 12/09/24
-0.10 (-2.47%)
since 11/20/24
3-Month
3.61 +9.42%
on 12/18/24
7.14 -44.68%
on 10/16/24
-2.40 (-37.80%)
since 09/20/24
52-Week
3.61 +9.42%
on 12/18/24
11.88 -66.75%
on 03/04/24
-0.40 (-9.20%)
since 12/20/23

Most Recent Stories

More News
C4 Therapeutics Reports Promising Phase 1 Clinical Trial Results for Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at ASH Annual Meeting

Cemsidomide shows promising response rates in multiple myeloma and non-Hodgkin's lymphoma, with manageable safety profiles.Quiver AI SummaryC4 Therapeutics, Inc. presented promising clinical data at the...

CCCC : 3.95 (+2.73%)
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

CCCC : 3.95 (+2.73%)
Unusual Options Activity: Strategies for Success with Three Single-Letter Stocks

Hidden within Wednesday’s 1,211 unusually active options were 22 calls and puts whose stock symbols have a single letter. It might not seem like a great investment strategy, but single-letter stocks...

AA : 37.84 (+3.33%)
C : 69.19 (+1.13%)
BAC : 44.17 (+1.82%)
D : 53.66 (+1.26%)
DDD : 3.50 (-1.41%)
JPM : 237.60 (+1.99%)
ICF : 59.84 (+1.77%)
CCCC : 3.95 (+2.73%)
NEE : 71.67 (+2.72%)
O : 52.79 (+1.99%)
C4 Therapeutics Appoints Steve Hoerter to Board of Directors to Strengthen Oncology Expertise

C4 Therapeutics appoints Steve Hoerter to its Board, enhancing oncology expertise to advance targeted protein degradation innovations.Quiver AI SummaryC4 Therapeutics, Inc. has announced the appointment...

CCCC : 3.95 (+2.73%)
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

CCCC : 3.95 (+2.73%)
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

CCCC : 3.95 (+2.73%)
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting

CCCC : 3.95 (+2.73%)
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

CCCC : 3.95 (+2.73%)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CCCC : 3.95 (+2.73%)
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

CCCC : 3.95 (+2.73%)

Business Summary

C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics...

See More

Key Turning Points

3rd Resistance Point 4.31
2nd Resistance Point 4.14
1st Resistance Point 4.05
Last Price 3.95
1st Support Level 3.79
2nd Support Level 3.62
3rd Support Level 3.53

See More

52-Week High 11.88
Fibonacci 61.8% 8.72
Fibonacci 50% 7.74
Fibonacci 38.2% 6.77
Last Price 3.95
52-Week Low 3.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar